ZA200404289B - Method of treatment - Google Patents

Method of treatment Download PDF

Info

Publication number
ZA200404289B
ZA200404289B ZA2004/04289A ZA200404289A ZA200404289B ZA 200404289 B ZA200404289 B ZA 200404289B ZA 2004/04289 A ZA2004/04289 A ZA 2004/04289A ZA 200404289 A ZA200404289 A ZA 200404289A ZA 200404289 B ZA200404289 B ZA 200404289B
Authority
ZA
South Africa
Prior art keywords
darifenacin
urgency
patients
pharmaceutically acceptable
overactive bladder
Prior art date
Application number
ZA2004/04289A
Other languages
English (en)
Inventor
Colli Enrico
Quinn Paul
Serdarevic Dzelal
Howard Skillern Laurence
Original Assignee
Aspen Global Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9927643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200404289(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aspen Global Incorporated filed Critical Aspen Global Incorporated
Publication of ZA200404289B publication Critical patent/ZA200404289B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Inorganic Insulating Materials (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Document Processing Apparatus (AREA)
  • Processing Of Meat And Fish (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
ZA2004/04289A 2001-12-14 2004-06-01 Method of treatment ZA200404289B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0129962.7A GB0129962D0 (en) 2001-12-14 2001-12-14 Method of treatment
PCT/IB2002/000664 WO2003051354A1 (en) 2001-12-14 2002-03-05 Method of treatment

Publications (1)

Publication Number Publication Date
ZA200404289B true ZA200404289B (en) 2005-09-28

Family

ID=9927643

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2004/04289A ZA200404289B (en) 2001-12-14 2004-06-01 Method of treatment

Country Status (27)

Country Link
US (3) US20030130338A1 (cg-RX-API-DMAC7.html)
EP (1) EP1458376B1 (cg-RX-API-DMAC7.html)
JP (3) JP2005516925A (cg-RX-API-DMAC7.html)
KR (1) KR100889086B1 (cg-RX-API-DMAC7.html)
CN (1) CN100488505C (cg-RX-API-DMAC7.html)
AT (1) ATE341323T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002236141B2 (cg-RX-API-DMAC7.html)
BR (1) BR0214925A (cg-RX-API-DMAC7.html)
CA (1) CA2469702C (cg-RX-API-DMAC7.html)
CY (1) CY1105814T1 (cg-RX-API-DMAC7.html)
CZ (1) CZ301283B6 (cg-RX-API-DMAC7.html)
DE (1) DE60215219T2 (cg-RX-API-DMAC7.html)
DK (1) DK1458376T3 (cg-RX-API-DMAC7.html)
ES (1) ES2276910T3 (cg-RX-API-DMAC7.html)
GB (1) GB0129962D0 (cg-RX-API-DMAC7.html)
HU (1) HU229908B1 (cg-RX-API-DMAC7.html)
IL (2) IL162391A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04005760A (cg-RX-API-DMAC7.html)
NO (1) NO20042586L (cg-RX-API-DMAC7.html)
NZ (1) NZ533421A (cg-RX-API-DMAC7.html)
PL (1) PL206034B1 (cg-RX-API-DMAC7.html)
PT (1) PT1458376E (cg-RX-API-DMAC7.html)
RU (1) RU2321398C2 (cg-RX-API-DMAC7.html)
SI (1) SI1458376T1 (cg-RX-API-DMAC7.html)
SK (1) SK287510B6 (cg-RX-API-DMAC7.html)
WO (1) WO2003051354A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200404289B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109142A2 (en) * 2006-03-17 2007-09-27 Oregon Health & Science University M3 muscarinic receptor antagonists for treating tumors
CN101084891A (zh) * 2007-06-29 2007-12-12 北京本草天源药物研究院 一种用于口服的达非那新或其药用盐的药物制剂
CZ200845A3 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
AU2010211725C1 (en) * 2009-02-04 2014-10-16 Astellas Pharma Inc. Pharmaceutical composition for oral administration
CN102048706B (zh) * 2011-01-12 2012-02-22 山东创新药物研发有限公司 一种氢溴酸达非那新缓释片及制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
US20090162433A1 (en) 2009-06-25
DK1458376T3 (da) 2007-02-12
SI1458376T1 (sl) 2007-06-30
PT1458376E (pt) 2007-01-31
NO20042586L (no) 2004-06-18
AU2002236141A1 (en) 2003-06-30
CA2469702A1 (en) 2003-06-26
IL162391A0 (en) 2005-11-20
MXPA04005760A (es) 2005-03-31
CY1105814T1 (el) 2011-02-02
KR100889086B1 (ko) 2009-03-16
GB0129962D0 (en) 2002-02-06
IL162391A (en) 2012-04-30
HUP0402625A2 (hu) 2005-04-28
CA2469702C (en) 2010-07-06
CN1604777A (zh) 2005-04-06
US8748476B2 (en) 2014-06-10
DE60215219T2 (de) 2007-10-18
ES2276910T3 (es) 2007-07-01
JP2013199506A (ja) 2013-10-03
RU2321398C2 (ru) 2008-04-10
NZ533421A (en) 2007-02-23
WO2003051354A1 (en) 2003-06-26
EP1458376A1 (en) 2004-09-22
JP2005516925A (ja) 2005-06-09
HK1073779A1 (zh) 2005-10-21
HU229908B1 (hu) 2014-12-29
CZ301283B6 (cs) 2009-12-30
CZ2004719A3 (cs) 2005-01-12
US20030130338A1 (en) 2003-07-10
SK287510B6 (sk) 2010-12-07
DE60215219D1 (de) 2006-11-16
RU2004121780A (ru) 2005-08-10
SK2502004A3 (en) 2004-10-05
AU2002236141B2 (en) 2007-02-01
BR0214925A (pt) 2004-12-21
US20070264333A1 (en) 2007-11-15
CN100488505C (zh) 2009-05-20
ATE341323T1 (de) 2006-10-15
KR20040066892A (ko) 2004-07-27
PL206034B1 (pl) 2010-06-30
EP1458376B1 (en) 2006-10-04
PL369426A1 (en) 2005-04-18
JP2010024244A (ja) 2010-02-04

Similar Documents

Publication Publication Date Title
US20220152057A1 (en) Methods and compositions for treating various disorders
Hennequin et al. Spondylodiskitis due to Candida albicans: report of two patients who were successfully treated with fluconazole and review of the literature
US8748476B2 (en) Darifenacin for use in the treatment of urgency induced by overactive bladder
JP4394686B2 (ja) 唾液分泌促進用医薬組成物およびその使用
HK1073779B (en) The use of darifenacin and the salt thereof
US20050234024A1 (en) Materials and methods for the treatment of ulcerative colitis
US20040116451A1 (en) Method of treatment
CN120390644A (zh) 雌四醇在肝损伤患者中的用途
JPH04266822A (ja) システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
JP4908448B2 (ja) 医薬製剤
JP2006290772A (ja) 多発性硬化症治療剤
AU2003259464A1 (en) Use of a quinazoline derivative for treating lower urinary tract symptoms
JPH10152442A (ja) 抗肥満剤